Literature DB >> 7650072

Oxytocin and desamino-oxytocin tablets are not stable under simulated tropical conditions.

A N de Groot1, Y A Hekster, T B Vree, P W van Dongen.   

Abstract

OBJECTIVES: This study is part of a programme on reduction of postpartum haemorrhage. Buccal oxytocin and desamino-oxytocin administration with a favourable effect on both blood loss and maternal morbidity and mortality were regarded as possible treatments for use in tropical countries. The stability of buccal oxytocin and desamino-oxytocin under tropical conditions was unknown and therefore tested in this study. STUDY
METHODS: The 'experimental shelf lives' of buccal oxytocin and desamino-oxytocin were examined by exposing the tablets to seven artificially controlled conditions. Samples were analysed by high performance liquid chromatography to determine the content of oxytocin and desamino-oxytocin at nine different times during the period of 1 year.
RESULTS: Oxytocin and desamino-oxytocin are fairly stable under refrigeration. Instability for both drugs was detectable after 20 weeks' storage under humid conditions, independent of temperature. Desamino-oxytocin is more sensitive to light exposure; its concentration declines to 55.6% of the stated amount after 1 year of exposure to light compared to 85% in the case of oxytocin. Oxytocin packaged as supplied by the manufacturer were stable for 21 weeks when exposed to simulated humid (75% relative humidity) conditions. At 40 degrees C and 25% relative humidity there is no difference in stability between tablets in sealed aluminium packs as supplied by the manufacturer and unpackaged tablets.
CONCLUSIONS: Tropical conditions make oxytocin and desamino-oxytocin tablets unstable, with humidity as the most adverse factor. The oxytocin tablets were partially protected from the harmful effect of humidity by sealed aluminium package.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650072     DOI: 10.1111/j.1365-2710.1995.tb00638.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products.

Authors:  Andrea Hawe; Robert Poole; Stefan Romeijn; Piotr Kasper; Rob van der Heijden; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-04-03       Impact factor: 4.200

2.  Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana.

Authors:  Cynthia Stanton; Alissa Koski; Patience Cofie; Ellie Mirzabagi; Breanne L Grady; Steve Brooke
Journal:  BMJ Open       Date:  2012-05-03       Impact factor: 2.692

3.  Accessibility and potency of uterotonic drugs purchased by simulated clients in four districts in India.

Authors:  Cynthia Stanton; Deepak Nitya Nand; Alissa Koski; Ellie Mirzabagi; Steve Brooke; Breanne Grady; Luke C Mullany
Journal:  BMC Pregnancy Childbirth       Date:  2014-11-13       Impact factor: 3.007

4.  The Quality of Selected Essential Medicines Sold in Accredited Drug Dispensing Outlets and Pharmacies in Tanzania.

Authors:  Eliangiringa Kaale; Vicky Manyanga; Mhina Chambuso; Jafary Liana; Edmund Rutta; Martha Embrey; Thomas Layloff; Keith Johnson
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

5.  Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability.

Authors:  Denis Kibira; Gaby Isabelle Ooms; Hendrika A van den Ham; Juliet Sanyu Namugambe; Tim Reed; Hubert Gm Leufkens; Aukje Mantel-Teeuwisse
Journal:  BMJ Open       Date:  2021-01-07       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.